A bill to require the Secretary of Health and Human Services to conduct a national, evidence-based education campaign to increase public and health care provider awareness regarding the potential risks and benefits of human cell and tissue products transplants, and for other purposes.
About This Bill
Committee
Latest Action · June 24, 2026
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The Shandra Eisenga Human Cell and Tissue Product Safety Act requires the Department of Health and Human Services to launch a national education campaign informing healthcare professionals and the public about the risks and benefits of human cell and tissue transplants, including information on organ and tissue donation procedures and donor screening tests. The bill establishes civil penalties of up to $20,000 per violation for companies that fail to comply with federal regulations governing these products, with additional penalties equal to the retail value of the products involved and a cap of $10 million per legal proceeding. The legislation also directs the FDA to publish educational materials and annual reports on the Tissue Reference Group, conduct stakeholder workshops, and submit recommendations to Congress by September 30, 2026, on modernizing the regulatory framework for these products. The bill affects tissue banks, healthcare facilities, and companies involved in cell and tissue product development and distribution, while benefiting patients seeking access to safe, regulated therapies.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.